



# Evaluation of a Rapid Diagnostic Assay for Detection of SARS-CoV-2 Antigen in Nasopharyngeal Swabs

Sidonie Lambert-Niclot,<sup>a,b</sup> Alexis Cuffel,<sup>c</sup> Samuel Le Pape,<sup>d</sup> Christelle Vauloup-Fellous,<sup>d</sup> Laurence Morand-Joubert,<sup>a,b</sup> Anne-Marie Roque-Afonso,<sup>d</sup> Jérôme Le Goff,<sup>c,e</sup> Constance Delaugerre,<sup>c,f</sup> on behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration

<sup>a</sup>INSERM-Sorbonne Universités UPMC, Université Paris 06, UMR-S 1136, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Paris, France

<sup>b</sup>Hôpital Saint-Antoine, Laboratoire de Virologie, Paris, France

<sup>c</sup>Hôpital Saint Louis, Laboratoire de Virologie, Paris, France

<sup>d</sup>Service de Virologie, Hôpital Paul-Brousse, INSERM U 1193, Université Paris-Saclay Villejuif, APHP Paris-Saclay, France

<sup>e</sup>Université de Paris, INSERM U976, Team Insight, Paris, France

<sup>f</sup>INSERM U944, Université de Paris, Paris, France

**KEYWORDS** antigen, SARS-CoV-2, rapid diagnostic test

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing coronavirus disease 2019 (COVID-19), was reported for the first time in Wuhan (Hubei Province, China) in December 2019 (1, 2) and has become a major public health concern all over the world. Early diagnosis is crucial for patient management and outbreak control. Most tests currently used for the detection of SARS-CoV-2 rely on viral RNA amplification by using real-time PCR (RT-PCR) and require a few hours before result release. Hence, highly sensitive immunological diagnostic methods that directly detect viral antigens in clinical samples would be very helpful for rapid and accurate diagnosis of COVID-19.

Here, we evaluated a rapid diagnostic test, COVID-19 Ag Respi-Strip (Coris Bio-Concept, Gembloux, Belgium), for detection of the SARS-CoV-2 antigen in nasopharyngeal secretions. The assay is ready to use and based on a nitrocellulose membrane technology with colloidal gold nanoparticles sensitized with monoclonal antibodies directed against highly conserved SARS-CoV-2 nucleoprotein antigens. We compared this test with RT-PCR, the current reference assay in virology laboratories of three university hospital groups from Assistance-Publique-Hôpitaux de Paris (APHP) (Saint-Antoine-Tenon-Trousseau, Saint-Louis-Lariboisière, and Kremlin Bicêtre-Paul Brousse). Different RT-PCR methods were used (RealStar [Altona Diagnostics], Bosphore novel coronavirus (2019-nCoV) detection kit [Anatolia Geneworks], Cobas 6800 [Roche], Allplex 2019 novel CoV assay [Seegene]). All assays amplify the SARS-CoV-2 E gene. Cycle threshold ( $C_T$ ) values were recorded. Nasopharyngeal samples were tested prospectively within a few hours after collection and without any cooling or freezing step, from 1 April to 15 April 2020. Swabs were collected in various transport media (COPAN's UTM [3 ml], Virocult [1 ml], ESwab Amies [1 ml], 4MRT [3 ml], 0.9% NaCl buffer, and cobas [Roche]). The first four samples collected in cobas medium tested gave invalid results. We therefore excluded such samples from the study. Our analysis included 138 nasopharyngeal samples, of which 94 (68.8%) were positive for SARS-CoV-2 by RT-PCR. Compared to that of RT-PCR, the specificity of the test was 100% (95% confidence intervals [95% CI], 91.8 to 100). Among the 94 RT-PCR-positive samples, the rapid test detected only 47 specimens, resulting in a sensitivity of 50.0% (95 CI, 39.5 to 60.5). In nine positive and eight negative tests, control lines were barely visible. Medians of E gene  $C_T$  values differed significantly between positive (median = 21; interquartile range [IQR], 17.0 to 23.0) and negative (median = 28.3; IQR, 25.6 to 33.0) antigenic test results

**Citation** Lambert-Niclot S, Cuffel A, Le Pape S, Vauloup-Fellous C, Morand-Joubert L, Roque-Afonso A-M, Le Goff J, Delaugerre C, on behalf of the AP-HP/Universities/INSERM COVID-19 Research Collaboration. 2020. Evaluation of a rapid diagnostic assay for detection of SARS-CoV-2 antigen in nasopharyngeal swabs. *J Clin Microbiol* 58:e00977-20. <https://doi.org/10.1128/JCM.00977-20>.


**Editor** Alexander J. McAdam, Boston Children's Hospital

**Copyright** © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Sidonie Lambert-Niclot, [sidonie.lambert@aphp.fr](mailto:sidonie.lambert@aphp.fr).

**Accepted manuscript posted online** 13 May 2020

**Published** 23 July 2020



**FIG 1** COVID-19 Ag Respi-Strip (Coris) results according to real-time PCR  $C_T$  values. All cycle threshold values of E gene real-time PCR-positive assays are shown for positive and negative COVID-19 Ag Respi-Strip assay results. Results gathering  $C_T$  values for all real-time PCR-positive assays are depicted by squares.  $C_T$  values between samples positive or negative for the antigenic assay are significantly different (\* indicates a  $P$  value of  $<0.0001$ ).  $C_T$  values corresponding to the Cobas 6800, Allplex, Anatolia, and RealStar assays are depicted by triangles, diamonds, circles, and upside-down triangles, respectively.

( $P < 0.0001$ ) (Fig. 1). A study conducted by the manufacturer mentioned a sensitivity of 76.7% for samples positive with a  $C_T$  value under 25 (3). In our study, the test had a sensitivity of 82.2% for  $C_T$  values under 25.

In our study, the COVID-19 Ag Respi-Strip (Coris) had a sensitivity of 50% compare to that of RT-PCR. The test was more sensitive for high viral loads and might perhaps be used for patients within a few days after symptom onset, when the load in the upper respiratory tract is at its peak. Considering COVID-19's current low prevalence of 0.19% in France, prospective studies should be conducted to determine the best settings for its implementation.

**REFERENCES**

- Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 395:497–506. [https://doi.org/10.1016/S0140-6736\(20\)30183-5](https://doi.org/10.1016/S0140-6736(20)30183-5).
- Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W, China Novel Coronavirus Investigating and Research Team. 2020. A novel coronavirus from patients with pneumonia in China, 2019. *N Engl J Med* 382:727–733. <https://doi.org/10.1056/NEJMoa2001017>.
- Mertens P, De Voe N, Martiny D, Jassoy C, Mirazimi A, Cuypers L, Van den Wijngaert S, Monteil V, Melin P, Stoffels K, Yin N, Mileto D, Delaunoy S, Magein H, Lagrou K, Bouzet J, Serrano G, Wautier M, Leclipteux T, Van Ranst M, Vandenberg O, LHUB-ULB SARS-CoV-2 Working Diagnostic Group. 8 May 2020. Development and potential usefulness of the COVID-19 Ag Respi-Strip diagnostic assay in a pandemic context. *Front Med* [https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?&utm\\_source=Email\\_to\\_authors&utm\\_medium=Email&utm\\_content=T1\\_11.5e1\\_author&utm\\_campaign=Email\\_publication&field=&journalName=Frontiers\\_in\\_Medicine&id=551560](https://www.frontiersin.org/articles/10.3389/fmed.2020.00225/full?&utm_source=Email_to_authors&utm_medium=Email&utm_content=T1_11.5e1_author&utm_campaign=Email_publication&field=&journalName=Frontiers_in_Medicine&id=551560).